North Caldwell, NJ, United States of America

Ronald A LeMahieu

This inventor holds 24 USPTO granted patents, primarily in Pharmaceutical Compositions. Top assignee: Hoffmann-La Roche Inc.. Active years: 1978-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald A LeMahieu. Retrieved from https://idiyas.com/inventor/ronald-a-lemahieu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24

% Patents Active = 100.0

Average Co-Inventor Count = 2.1

ph-index = 10

Forward Citations = 276(Granted Patents)

Location History:

Caldwell, NJ (US) (1985)
North Caldwell, NJ (US) (1978 - 1994)
N. Caldwell, NJ (US) (1994 - 1995)

Company Filing History:

24 out of 5,028

Hoffmann-La Roche Inc.

patents

Years Active: 1978-1995

Loading Chart...

Areas of Expertise:

N-Substituted Anilines

Phospholipase Inhibitors

Catechol Carboxylic Acids

Dihydroxynaphthalene Derivatives

Phenoxycarboxylic Acids

Substituted Naphthalene

Tetrazoles

Antibiotic Production

Pharmaceutical Compositions

Carboxylic Acids

Naphthalenyloxy Compounds

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5446189 - Intermediates for the production of N-substituted anilines, inhibitors (1995-08-29),

2. 5374772 - Substituted benzoic acids, inhibitors of phospholipases A.sub.2 (1994-12-20),

3. 5344843 - Cat-1 inhibitors, pharmaceutical compositions and methods of use (1994-09-06),

4. 5324747 - N-substituted anilines, inhibitors of phospholipases A.sub.2 (1994-06-28),

5. 5298652 - N-substituted glycines, inhibitors of phospholipase A.sub.2 (1994-03-29),

6. 5191108 - Catechol carboxylic acids (1993-03-02),

7. 5025036 - Catechol carboxylic acids (1991-06-18),

8. 4937373 - Substituted naphthalene carboxylic acids (1990-06-26),

9. 4937371 - Dihydroxynaphthalene derivatives (1990-06-26),

10. 4916145 - Substituted n-[(pyridyl)alkyl]aryl-carboxamide (1990-04-10),

11. 4782176 - Phenoxycarboxylic acids (1988-11-01),

12. 4672066 - Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids (1987-06-09),

13. 4663332 - 5-substituted N-alkylated tetrazoles (1987-05-05),

14. 4628115 - Substituted 4-acetyl-3-hydroxyphenoxy alkanoic acids (1986-12-09),

15. 4616091 - Naphthalenyloxy carboxylic acids (1986-10-07),

Title: Ronald A. LeMahieu: Innovator in Pharmaceutical Chemistry

Introduction: Ronald A. LeMahieu, based in North Caldwell, NJ, is a prominent figure in the field of pharmaceutical chemistry. With a remarkable portfolio that includes 24 patents, he has made significant contributions to the development of novel therapeutic compounds aimed at treating various inflammatory diseases.

Latest Patents: Ronald's latest patents encompass pivotal innovations, including intermediates for the production of N-substituted anilines and compounds that act as potent inhibitors of phospholipases A2 (PLA2s). These innovative compounds are particularly valuable for the treatment of conditions such as psoriasis, inflammatory bowel disease, asthma, allergies, arthritis, dermatitis, gout, and myocardial ischemia/reperfusion. The therapeutic potential of these compounds is further enhanced when derivatives that are pharmaceutically acceptable salts with bases are developed. Another notable patent involves substituted benzoic acids as inhibitors of phospholipases A2, highlighting Ronald's commitment to addressing complex health issues through innovative chemical solutions.

Career Highlights: Ronald A. LeMahieu has built a distinguished career at Hoffmann-La Roche Inc., a leading entity in the pharmaceutical industry. His research and development efforts have focused on creating novel compounds that offer new treatments for challenging medical conditions, showcasing his capability to bridge the gap between innovative chemistry and practical medical application.

Collaborations: Throughout his career, Ronald has collaborated with esteemed colleagues, including Ru-Jen L. Han and Matthew Carson. These partnerships have fostered an environment of shared knowledge and expertise, leading to advancements in pharmaceutical innovation and contributing to the success of their joint research efforts.

Conclusion: Ronald A. LeMahieu stands out as a dedicated inventor whose work has the potential to make a significant impact on the health sector. His ongoing innovations in pharmaceutical intermediates and inhibitors of phospholipases A2 demonstrate his commitment to improving therapeutic options for patients. As he continues his work at Hoffmann-La Roche Inc., the medical community eagerly anticipates further advancements arising from his research endeavors.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]